Valproate Alters Dopamine Signaling in Association with Induction of Par-4 Protein Expression

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Lee, Saebom ^a   Jeong, Jaehoon ^a   Park, Young Un ^a   Kwak, Yongdo ^a   Lee, Seol Ae ^a   Lee, Haeryun ^a   Son, Hyeon ^b   Park, Sang Ki ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; DOPAMINE; DOPAMINE 2 RECEPTOR; HISTONE H3; HISTONE H4; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 4; SULPIRIDE; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; GENE; HISTONE ACETYLATION; INTRACELLULAR SIGNALING; MALE; MOUSE; NERVE CELL CULTURE; NEUROMODULATION; NONHUMAN; PAR 4 GENE; PHARMACOLOGICAL STIMULATION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; TREATMENT DURATION;

ANIMALS; BASE SEQUENCE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; DOPAMINE; HIPPOCAMPUS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, DOPAMINE D2; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION; VALPROIC ACID;

EID: 84866646989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045618     Document Type: Article

References (37)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, et al. (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593-602.
2. Goodwin FK, Ghaemi SN, (1998) Understanding manic-depressive illness. Arch Gen Psychiatry 55: 23-25.
3. Mill J, Petronis A, (2007) Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry 12: 799-814.
4. Tsankova N, Renthal W, Kumar A, Nestler EJ, (2007) Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8: 355-367.
5. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, et al. (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9: 519-525.
6. Lee S, Jeong J, Kwak Y, Park SK, (2010) Depression research: where are we now? Mol Brain 3: 8.
7. Ramakrishnan V, (1997) Histone structure and the organization of the nucleosome. Annu Rev Biophys Biomol Struct 26: 83-112.
8. Strahl BD, Allis CD, (2000) The language of covalent histone modifications. Nature 403: 41-45.
9. Schroeder FA, Lin CL, Crusio WE, Akbarian S, (2007) Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 62: 55-64.
10. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
11. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK, (2004) Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 9: 734-755.
12. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
13. Panomvana Na Ayudhya D, Suwanmanee J, Visudtibhan A, (2006) Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Am J Ther 13: 211-217.
14. Goodwin GM, (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17: 149-173; discussion 147.
15. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM, (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14: 51-59.
16. Park SK, Nguyen MD, Fischer A, Luke MP, Affar el B, et al. (2005) Par-4 links dopamine signaling and depression. Cell 122: 275-287.
17. Nau H, Loscher W, (1982) Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse. J Pharmacol Exp Ther 220: 654-659.
18. Glantz LA, Gilmore JH, Overstreet DH, Salimi K, Lieberman JA, et al. (2010) Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophr Res 118: 292-299.
19. Nader K, Bechara A, van der Kooy D, (1997) Neurobiological constraints on behavioral models of motivation. Annu Rev Psychol 48: 85-114.
20. Bowden C, Cheetham SC, Lowther S, Katona CL, Crompton MR, et al. (1997) Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res 769: 135-140.
21. Papp M, Klimek V, Willner P, (1994) Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl) 115: 441-446.
22. Basso AM, Gallagher KB, Bratcher NA, Brioni JD, Moreland RB, et al. (2005) Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology 30: 1257-1268.
23. Zhu X, Peng S, Zhang S, Zhang X, (2011) Stress-induced depressive behaviors are correlated with Par-4 and DRD2 expression in rat striatum. Behav Brain Res 223: 329-335.
24. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM, (2002) Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80: 589-597.
25. Aubry JM, Schwald M, Ballmann E, Karege F, (2009) Early effects of mood stabilizers on the Akt/GSK-3beta signaling pathway and on cell survival and proliferation. Psychopharmacology (Berl) 205: 419-429.
26. Omata N, Murata T, Takamatsu S, Maruoka N, Mitsuya H, et al. (2008) Neuroprotective effect of chronic lithium treatment against hypoxia in specific brain regions with upregulation of cAMP response element binding protein and brain-derived neurotrophic factor but not nerve growth factor: comparison with acute lithium treatment. Bipolar Disord 10: 360-368.
27. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, et al. (2008) Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28: 2576-2588.
28. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS, (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278: 33067-33077.
29. Jonathan Ryves W, Dalton EC, Harwood AJ, Williams RS, (2005) GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord 7: 260-265.
30. Chen G, Huang LD, Jiang YM, Manji HK, (1999) The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72: 1327-1330.
31. Hall AC, Brennan A, Goold RG, Cleverley K, Lucas FR, et al. (2002) Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci 20: 257-270.
32. De Sarno P, Li X, Jope RS, (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158-1164.
33. Tatebayashi Y, Haque N, Tung YC, Iqbal K, Grundke-Iqbal I, (2004) Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport. J Cell Sci 117: 1653-1663.
34. Wells J, Farnham PJ, (2002) Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. Methods 26: 48-56.
35. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M, (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103: 843-852.
36. Park YU, Jeong J, Lee H, Mun JY, Kim JH, et al. (2010) Disrupted-in-schizophrenia 1 (DISC1) plays essential roles in mitochondria in collaboration with Mitofilin. Proc Natl Acad Sci U S A 107: 17785-17790.
37. Qi Y, Wang JK, McMillian M, Chikaraishi DM, (1997) Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. J Neurosci 17: 1217-1225.